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A B S T R A C T
Pre-eclampsia is a leading cause of maternal death and maternal and perinatal morbidity. Whilst the clinical
manifestations of pre-eclampsia often occur in late pregnancy, the molecular events leading into the onset of this
disease are thought to originate in early pregnancy and result in insufWcient placentation. Although the causative
molecular basis of pre-eclampsia remains poorly understood, maternal inXammation is recognised as a core clin-
ical feature. While the adverse effects of pre-eclampsia on maternal and fetal health in pregnancy is well-recog-
nised, the long-term impact of pre-eclampsia exposure on the risk of autism spectrum disorder (ASD) in exposed
oZspring is a topic of on-going debate. In particular, a recent systematic review has reported an association be-
tween exposure to pre-eclampsia and increased risk of ASD, however the molecular basis of this association is
unknown. Here we review recent evidence for; 1) maternal inXammation in pre-eclampsia; 2) epidemiological
evidence for alterations in neurodevelopmental outcomes in oZspring exposed to pre-eclampsia; 3) long-term
changes in the brains of oZspring exposed to pre-eclampsia; and 4) how maternal inXammation may lead to al-
tered neurodevelopmental outcomes in pre-eclampsia exposed oZspring. Finally, we discuss the implications of
this for the development of future studies in this Weld.
1. Introduction
Autism spectrum disorder (ASD) is a complex neurodevelopmental
disorder, characterised by impairments in social and communication
skills, as well as restricted and repetitive patterns of behaviour (Lord et
al., 2018; Thapar et al., 2017; Xiao et al., 2014). ASD is among the most
common neurodevelopmental conditions with a prevalence of approxi-
mately 1% globally, and 1.5% in developed countries (Lord et al., 2018;
Lyall et al., 2017).
While there is a general consensus that genetics play the major
role in the aetiology of ASD (Sandin et al., 2014), the environmental
contribution is estimated to be between 17 50%. (Sandin et al.,
2017, 2014). Therefore, it is important to investigate factors potentially
contributing to the likelihood of development of ASD. Several environ-
mental risk factors, including prenatal and perinatal factors have been
examined in an attempt to explain the aetiology of ASD (Lord et al.,
2018). In particular, a recent systematic review examining the asso-
ciation between hypertensive disorders of pregnancy (HDP) and neu-
rodevelopmental disorders reported an association between pre-eclamp-
sia and ASD in exposed oZspring (Maher et al., 2018). However, while
the molecular basis of this association is not known, it may involve
maternal inXammation given its link to ASD (Brown et al., 2014),
and given that maternal inXammation is a core
Abbreviations: ADHD, attention deWcit hyperactivity disorder; ASD, autism spectrum disorder; DTI, diffusion tensor MR imaging; HDP, hypertensive disorders of pregnancy; ID, in-
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feature of pre-eclampsia (Lau et al., 2013) (Fig. 1). Therefore, the objec-
tives of this paper are to review and provide a perspective on the:
1 Evidence for maternal inXammation in pre-eclampsia;
2 Epidemiological evidence for alterations in neurodevelopmental out-
comes in oZspring exposed to pre-eclampsia;
3 Evidence for long-term changes in the brains of oZspring exposed to
pre-eclampsia;
4 Evidence for how maternal inXammation may lead to altered neu-
rodevelopmental outcomes in pre-eclampsia exposed oZspring.
2. Hypertensive disorders of pregnancy
Hypertensive disorders of pregnancy (HDP) may be chronic (pre-dat-
ing pregnancy or diagnosed before 20 weeks gestation) or arise de
novo (either pre-eclampsia or gestational hypertension). HDP are one
of the most common gestational complications affecting 3 10% of all
pregnancies and are made up of a collection of hypertensive condi-
tions including pre-existing hypertension (chronic hypertension), gesta-
tional hypertension, white coat hypertension and pre-eclampsia (Brown
et al., 2018a). Of these, pre-eclampsia is one of the leading causes of
maternal mortality and morbidity and has recently been redeWned by
the International Society for the study of Hypertension in Pregnancy
(ISSHP) as gestational hypertension (systolic BP > 140 and/or diastolic
BP > 90 mmHg) accompanied by one or more of the following new-on-
set conditions at or after 20 weeks gestation (Brown et al., 2018b):
1 Proteinuria;
2 Other maternal organ dysfunction, including:
Acute kidney injury (creatinine > 90umol/L; 1 mg/dL)
Liver involvement (elevated transaminases e.g. ALT or AST > 40 IU/
L) with or without right upper quadrant or epigastric abdominal pain)
Neurological complications (examples include eclampsia, altered
mental status, blindness, stroke, clonus, severe headaches, persistent
visual scotomata)
Haematological complications (thrombocytopenia platelet count be-
low 150,000/uL, DIC, hemolysis)
3 Uteroplacental dysfunction (such as fetal growth restriction, abnor-
mal umbilical artery Doppler wave form analysis, or stillbirth).
Previously thought to be simply due to impaired trophoblast in-
vasion followed by the development of the clinical manifestations of
the disease, it is now appreciated that the underlying aetiology of
pre-eclampsia is far more complex. Beginning with genetic susceptibil-
ity, followed by an abnormal immune adaptation to pregnancy, this in
turn leads to impaired placentation and the subsequent perfusion of
the intervillous space by oxygenised arterial blood resulting in exces-
sive or de cient placental derived factors in the maternal circulation
(Chaiworapongsa et al., 2014a, b). The endothelial dysfunction, result-
ing from placental ischemia and release of placental products which oc-
curs in pre-eclampsia appears to occur as a result of oxidative stress and
is mediated by high levels of free radicals and low levels of antioxidants
(Roberts and Cooper, 2001; Roberts and Gammill, 2005; Roberts and
Hubel, 2004; Roberts and Lain, 2002; Roberts and Speer, 2004; Roberts
et al., 1989). Vasoactive factors released include soluble fms-like tyro-
sine kinase-1 (sFlt-1), cytokines, angiotensin II and type 1 receptor au-
toantibodies (Conrad and Benyo, 1997; Maynard et al., 2003; Rinehart
et al., 1999; Roberts et al., 1991; Wallukat et al., 1999). These fac-
tors target the maternal vascular endothelium giving rise to the ma-
ternal syndrome of hypertension, proteinuria, organ and uteroplacen-
tal dysfunction which may be followed by acute atherosis in the spi-
ral arteries predisposing to spiral artery thrombosis and placental in-
farcts (Lindheimer and Katz, 1981; Redman, 2014). In addition, there is
an increasing awareness that pre-eclampsia leads to a state of exagger-
ated maternal inXammation as a direct result of the underlying patho-
physiology, and perhaps also indirectly by risk factors such as mater-
nal obesity which is known to lead to chronic low-grade inXammation
(Chaiworapongsa et al., 2014b; Jaaskelainen et al., 2018; Nelson et al.,
2010; Segovia et al., 2014; Spradley et al., 2015). Therefore pre-eclamp-
sia may be a common cause of maternal inXammation during preg-
nancy, which is a recognised risk factor for adverse neurodevelopmental
outcomes (Knuesel et al., 2014). Consequently, there has been a grow-
ing interest in studying maternal inXammation and subsequently neu-
rodevelopmental outcomes in oZspring exposed to pre-eclampsia.
3. Maternal in/ammation in pre-eclampsia: a potential role for
Interleukin-6 and tumor necrosis factor (TNF)- ?
In uncomplicated pregnancies there is a normal systemic inXamma-
tory response in which cytokines promote the inWltration of the spi-
ral arteries by invading trophoblast cells (Redman et al., 1999). This
is an important feature of normal placentation and occurs early in
pregnancy. However this normal inXammatory response becomes ex-
aggerated in pre-eclampsia resulting in disruptive activation of mono-
cytes, granulocytes and the endothelium resulting in a state of ma-
ternal inXammation (Redman and Sargent, 2003). It has been pro
Fig. 1. Schema showing an overview of how pre-eclampsia may impact neurodevelopmental outcomes in exposed oZspring. While physiological levels of maternal inXammation plays a
role in an uncomplicated pregnancy, the decrease in placental perfusion in pre-eclampsia leads to the increased production of pro-inXammatory cytokines including IL-6 and TNF- . These
cytokines may disrupt placenta signalling and/or cross to the fetal circulation to alter fetal neurodevelopmental trajectories, which may increase the risk of sub-optimal neurodevelopmen-
tal outcomes in oZspring exposed to pre-eclampsia.
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posed that there may be a genetic susceptibility to inXammation in
pre-eclampsia yet many studies are conXicting (for recent review see
(Thakoordeen et al., 2018). A meta-analysis of maternal polymorphisms
in interleukin (IL)-6 (174 G/C) (n = 396 pre-eclampsia and n = 507
normotensive) and tumor necrosis factor (TNF)- (308 G/A) (n = 1888
pre-eclampsia and n = 2497 normotensive) found that these were not
associated with pre-eclampsia, despite maternal IL-6 and TNF- lev-
els being significantly higher in patients with pre-eclampsia (Xie et
al., 2011). This suggests that elevations in cytokines may be as a re-
sult of the primary pathophysiology. However some subsequent stud-
ies have reported opposing Wndings (Sowmya et al., 2015) and this
remains a topic of on-going investigation (Thakoordeen et al., 2018).
However what is clear is that many clinical studies have now reported
that women with pre-eclampsia have increased levels of inXammatory
cytokines including IL-6, TNF- , IL-12 and IL-16, which cause structural
and functional changes in endothelial cells, promote the formation of
endothelin and reduce acetylcholine induced vasodilatation (Benyo et
al., 2001; Conrad and Benyo, 1997; Greer et al., 1994; Gu et al., 2008;
Kupferminc et al., 1994; Lefer and Ma, 1993; Marsden and Brenner,
1992; Meekins et al., 1994; Pober and Cotran, 1990; Vince et al., 1995;
Visser et al., 1994). A systematic review and meta-analysis published in
2013 tested the association between pre-eclampsia and maternal circu-
lating levels of IL-6 (n = 425 pre-eclampsia and n = 363 normotensive),
IL-10 (n = 180 pre-eclampsia and n = 175 normotensive) and TNF- (n
= 1015 pre-eclampsia and n = 925 normotensive) (Lau et al., 2013).
Third trimester maternal circulating levels of IL-6, IL-10 and TNF- were
significantly higher in women with pre-eclampsia compared to nor-
motensive controls (Lau et al., 2013). Subsequently a number of studies
have extended and corroborated these Wndings.
A study by Mihu et al examined maternal cytokine concentrations
between 28 and 41 weeks gestation in an uncomplicated pregnancy
group (n = 78), a pre-eclampsia group (n = 80), and a non-pregnant
control group (n = 72) and reported elevations in IL-6 and TNF- in
the pre-eclampsia group (Mihu et al., 2015). In support of this, a study
by Valencia-Ortega et al also examined IL-6 levels in age-matched
pregnant women with (n = 50) and without pre-eclampsia (n = 50).
They reported that maternal serum concentrations of IL-6 were sig-
nificantly higher in late-onset pre-eclampsia, compared to early-on-
set pre-eclampsia or uncomplicated pregnancy (Valencia-Ortega et al.,
2018). Moreover while mid-gestation circulating IL-6 levels were asso-
ciated with pre-eclampsia, IL-6 was only significantly associated with
term pre-eclampsia, suggesting that elevations in IL-6 may be a late
stage feature of pre-eclampsia (Taylor et al., 2016b). This is consistent
with a study of women with pre-eclampsia (n = 208) and normotensive
controls (n = 411) which showed that Wrst and second trimester levels
of IL-6 were not associated with pre-term pre-eclampsia (Taylor et al.,
2016a). Interestingly given that we and others have reported that the
stage of pregnancy in which oZspring are exposed to maternal inXam-
mation is a key determinant of neurodevelopmental outcomes in ex-
posed oZspring (Aguilar-Valles and Luheshi, 2011; Boksa, 2010; Fortier
et al., 2007; Meyer et al., 2006; Straley et al., 2014, 2017), it is possi-
ble that the effects of pre-eclampsia on oZspring neurodevelopmental
outcomes may vary depending on the severity and clinical course of the
disease.
These Wndings are also supported by animal modelling of the patho-
physiological mechanisms that underlie the development of pre-eclamp-
sia. Specifically, the reduced uterine perfusion pressure (RUPP) rat
model of placental ischemia mimics many of the clinical character-
istics of pre-eclampsia. Placental ischaemia generated by reductions
in uterine perfusion pressure in pregnant rats increases blood pres-
sure, reduces glomerular Wltration rate (GFR), increases sFlt-1 con-
centrations, elevates production of pro-inXammatory cytokines and re-
active oxygen species (ROS) and leads to intrauterine
growth restriction (IUGR) (Granger et al., 2006). Recent studies in the
RUPP model have described an immune imbalance characterised by in-
creased pro-inXammatory CD4⁠+ T cells and pro-inXammatory cytokines
in addition to a reduction in regulatory T cells and anti-inXammatory
cytokines (Cornelius, 2018). Specifically there is substantial evidence of
increased serum levels of pro-inXammatory cytokines IL-6 (Gadonski et
al., 2006) and TNF- (LaMarca et al., 2008) in response to placental is-
chemia in the RUPP model compared to sham controls. Initial work in-
fusing TNF- at day 14 of gestation in pregnant rats reported a signif-
icant increase in mean arterial blood pressure and a reduction in renal
iNOS production coincident with two-fold increase in plasma TNF- lev-
els (Alexander et al., 2002). This work was extended to examine the role
of endothelin in mediating the effect of TNF- -induced hypertension in
pregnant rats (LaMarca et al., 2005). The TNF- -induced hypertension
was associated with an increase in preproendothelin expression in pla-
centa, aorta and kidneys. Additionally, pre-treating these pregnant rats
with an endothelin receptor A antagonist prior to TNF- infusion abol-
ished the increase in mean arterial pressure. Interestingly, chronic in-
fusion of TNF- had no effect on mean arterial blood pressure in vir-
gin rats (LaMarca et al., 2005). Furthermore, inhibition of TNF- using
the soluble receptor etanercept significantly reduced mean arterial pres-
sure and rescued fetal growth restriction in RUPP rats (LaMarca et al.,
2008). A study by Gadonski et al examined the role of IL-6 in generating
pre-eclampsia-like characteristics by infusing pregnant rats with IL-6 for
5 days resulting in a 2 3 fold increase in serum IL-6 levels. As a result
of the increase in circulating IL-6 levels these rats had elevated mean
arterial pressure, reduced renal plasma Xow and reduced glomerular
Wltration rates (Gadonski et al., 2006). Interestingly, these pre-eclamp-
sia-like characteristics were not evident in virgin rats infused with IL-6
(Gadonski et al., 2006). These data indicate that elevations in mater-
nal IL-6 may be part of the maternal inXammatory pathophysiology of
pre-eclampsia.
4. The epidemiological evidence for alterations in
neurodevelopmental outcomes in o0spring exposed to pre-
eclampsia
We recently conducted a systematic review synthesising published,
epidemiological evidence examining the association between HDP and
neurodevelopmental disorders in the oZspring (Maher et al., 2018). The
primary outcomes included in the review were ASD and attention deWcit
hyperactivity disorder (ADHD). Secondary outcomes included behav-
ioural outcomes such as Asperger s Syndrome, Pervasive Developmental
Disorder - Not Otherwise SpeciWed (PDD-NOS), behavioural difWculties
using standardised checklists, as well as cognitive functioning, devel-
opmental delay and intellectual disability. In total, 61 papers were in-
cluded in the review: 20 for ASD (six cohort studies and 14 case-control
studies), 10 for ADHD (Wve cohort studies and Wve case-control studies)
and 31 secondary outcome papers (25 cohort studies and six case-con-
trol studies).
Pooled results from this study showed that exposure to HDP (includ-
ing pre-eclampsia, gestational hypertension and chronic hypertension)
was associated with a 35% increase in the odds of ASD when compared
to those unexposed to HDP (OR = 1.35; 95% CI: 1.11 1.64) (Maher et
al., 2018). Subgroup analysis examining pre-eclampsia alone and ASD
increased the odds ratio to 1.50 (95% CI: 1.26 1.78), whereas all other
HDP (which may include pre-eclampsia) were associated with a non-sig-
nificant increase in the odds of ASD (OR: 1.25, 95% CI: 0.90 1.73)
(Maher et al., 2018) (see Table 1). However, it is important to note
that the epidemiological evidence in this area is largely inconsistent.
For example, some studies suggested that exposure to pre-eclampsia
may be associated with a statistically significant increase in the like-
lihood of ASD, when com
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Table 1
Summary of studies examining preeclampsia and ASD.
Author Design N Prenatal Stressor Outcomes Results
cOR/RR
(95%
CI)
aOR/RR
(95%
CI)
Walker et al.,
2015
Case-
control
867 PE from medical records or maternal
self-reporting in telephone interview
ADOS
ADI-R
odds
ASD*
2.58
(1.31,
5.11)
2.36
(1.18,
4.72)
Mrozek-Budzyn
et al., 2013
Case-
control
288 PE from medical records or self-
reporting
ICD-10 odds
ASD
2.05
(0.58,
7.28)
Lyall et al.,
2012
Cohort 66445 Toxemia self-reported in questionnaire Maternal-reported odds
ASD*
1.24
(0.99,
1.55)
1.36
(1.04,
1.78)
Burstyn et al.,
2010
Cohort 216342 PE from APHP delivery records ICD-9 odds
ASD
1.91
(1.30,
2.81)
1.49
(1.00,
2.22)
Mann et al.,
2010
Cohort 87677 PE/eclampsia from billing records for
Medicaid-eligible women (ICD-9)
ICD-9 from Medicaid billing records or DDSN odds
ASD*
1.85
(1.38,
2.48)
1.69
(1.26,
2.27)
Buchmayer et
al., 2009
Case-
control
7296 PE from MBR (ICD-9, ICD-10) ICD-9, ICD-10 odds
ASD*
1.41
(0.98,
2.03)
1.64
(1.08,
2.49)
Larsson et al.,
2005
Case-
control
18148 PE from MBR ICD-8 and ICD-10 from PCR odds
ASD
1.54
(0.83,
2.86)
Glasson et al.,
2004
Case-
control
1627 PE (ICD-9) DSM odds
ASD
0.90
(0.50,
1.62)
Eaton et al.,
2001
Case-
control
103021 Eclampsia from MBR ICD from PCR odds
ASD
0.82
(NR)
Matsuishi et
al., 1999
Case-
control
232 Toxemia DSM-III-R odds
ASD
0.82
(0.18,
3.79)
Mason-Brothers
et al., 1990
Case-
control
285 Toxemia from medical records DSM-III odds
ASD
0.36
(0.16,
0.83)
Deykin and
MacMahon,
1980
Case-
control
364 Toxemia from medical records and
interview data
1 symptoms of impaired relatedness to the
environment, stereopathy and impaired language
development
odds
ASD
0.83
(0.25,
2.70)
0.90
(0.50,
1.62)
*Adjusted result was statistically signiWcant.
95% conWdence interval (95% CI); Preeclampsia (PE); Autism Diagnostic Observation Schedule (ADOS); Autism Diagnostic Interview, Revised (ADI-R); Alberta Perinatal Health Program
(APHP); Department of Disabilities and Special Needs, South Carolina (DDSN); Medical Birth Register (MBR); Psychiatric Central Register (PCR); Diagnostic and Statistical Manual of
Mental Disorders (DSM); not reported (NR); Diagnostic and Statistical Manual of Mental Disorders 3rd Edition Revised (DSM-III-R).
pared to unexposed oZspring (Buchmayer et al., 2009; Curran et al.,
2018; Dodds et al., 2011; Lyall et al., 2012; Mann et al., 2010; Nath et
al., 2012; Polo-Kantola et al., 2014; Walker et al., 2015), while others
proposed a positive other HDP-ASD relationship (Curran et al., 2018;
Dodds et al., 2011; Nath et al., 2012; Polo-Kantola et al., 2014). Sim-
ilarly, there are studies that alluded to a positive pre-eclampsia-ASD
relationship, (Bilder et al., 2009; Buchmayer et al., 2009; Burstyn et
al., 2010; Hultman et al., 2002; Krakowiak et al., 2012; Larsson et
al., 2005; Mrozek-Budzyn et al., 2013) and others a HDP-ASD relation-
ship (Bilder et al., 2009; Buchmayer et al., 2009; Hultman et al., 2002;
Krakowiak et al., 2012) but failed to meet statistical significance. Con-
versely, some older studies are suggestive of a protective association be-
tween pre-eclampsia and ASD (Deykin and MacMahon, 1980; Glasson et
al., 2004; Langridge et al., 2013; Lyall et al., 2012; Mason-Brothers et
al., 1990; Matsuishi et al., 1999), and other HDP-ASD (Lyall et al., 2012;
Langridge et al., 2013), but only two of these found a statistically signif-
icant relationship (Langridge et al., 2013; Mason-Brothers et al., 1990).
Given the non-significant pooled estimate seen with other HDP and
ASD, it is difWcult to hypothesise whether the type of HDP is an im-
portant factor in determining the impact on ASD risk in exposed oZ-
spring. The subgroup analysis by Maher et al (Maher et al., 2018) re-
ported a highly statistically significant association between pre-eclamp-
sia and ASD but a non-significant risk of ASD with other HDP (in-
cluding pre-eclampsia). This may suggest that the association observed
occurs not as a result of exposure to hypertension but as a re
sult of exposure to a mediator of the complex syndrome of pre-eclamp-
sia such as inXammation. More research is needed on the associa-
tion between the type of HDP and ASD in order to examine whether
pre-eclampsia only, or all HDP display a significant association with
ASD.
Although the Wndings show an apparent HDP-ASD relationship, re-
sults may need to be interpreted with caution as several limitations were
identiWed among ASD studies. Firstly, misclassiWcation bias could have
resulted from a lack of validated questionnaires and maternal reporting
of exposure and ASD status when determining exposure and outcome
status of subjects (Curran et al., 2018; Krakowiak et al., 2012; Lyall
et al., 2012; Walker et al., 2015). Secondly, confounding is of partic-
ular concern in observational studies due to the lack of randomisation
process, potentially leading to spurious Wndings. The vast majority of
studies identiWed in the systematic review failed to control for a combi-
nation of key variables, calling into question the validity of Wndings. For
example, only one study controlled for a combination of key variables
such as maternal age, socio-economic status, ethnic origin and maternal
depression (Curran et al., 2018). Finally, several studies contained small
sample sizes, evident in 5 of 20 studies which had fewer than 10 cases
of ASD exposed to HDP (Bilder et al., 2009; Deykin and MacMahon,
1980; Matsuishi et al., 1999; Mrozek-Budzyn et al., 2013; Nath et al.,
2012). However, results of larger studies (> 10 exposed cases) that con-
trolled for at least one potential confounder in the analysis phase of the
study ranged from an OR of 1.36 to 2.36 for pre-eclampsia and 0.96 to
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2.83 for other HDP (which may have included pre-eclampsia) (Maher et
al., 2018).
In addition, while the results of the systematic review also suggest
an association between pre-eclampsia and ASD, this association may not
be speciWc to ASD (Maher et al., 2018). For example, adjusted pooled
results in Maher et al also proposed that oZspring exposed to HDP were
30% more likely to have ADHD compared to those unexposed. Sub-
group analyses investigating a pre-eclampsia-ADHD relationship in iso-
lation did not change this estimate, while the odds of ADHD was as-
sociated with a 70% increase in relation to other HDP (Maher et al.,
2018). Moreover, while the evidence remains inconsistent among sec-
ondary outcome studies included in the review, there were some pat-
terns of association between HDP and intellectual disability (ID) despite
methodological differences between studies (Eaton et al., 2001; GriYth
et al., 2011; Langridge et al., 2013; Salonen and Heinonen, 1984). For
example, results from GriYth et al, 2011 suggested that pre-eclampsia/
eclampsia was associated with a 38% increase in the odds of ID (95%
CI: 1.16, 1.64) (GriYth et al., 2011). Similarly, the relative risk for an
eclampsia- mental retardation relationship classiWed according to ICD
coding was 3.03 in Danish oZspring less than 15 years old (Eaton et al.,
2001). Langridge et al measured ID using the American Association on
Mental Retardation classiWcation system and suggested an association
between HDP and moderate ID in Western Australia (OR: 1.39, 95% CI:
1.25, 1.54) (Langridge et al., 2013). Lastly, Salonen and Heinonen used
a standardised set of tests for mental performance and suggested that
HDP was associated with an increased likelihood of mental retardation
in children aged 9 10 years in Eastern Finland (RR: 6.1, 95% CI: 1.3,
28.9) (Salonen and Heinonen, 1984).
Collectively, the epidemiological evidence points to an apparent
relationship between pre-eclampsia exposure in particular, and ASD
risk in exposed oZspring. However, the speciWcity of the effects of
pre-eclampsia on ASD risk, could in fact be associated with poor neu-
rodevelopmental outcome in general as opposed to being speciWc to
ASD (Bodnar et al., 2018). Given the available evidence that
pre-eclampsia and other HDPs may impact neurodevelopmental out-
comes (Maher et al., 2018), there has been an increasing focus on identi-
fying any neuroanatomical alterations in the brain of oZspring exposed
to pre-eclampsia.
5. Evidence for long-term changes in the brains of o0spring
exposed to pre-eclampsia
An increasing body of work has now shown that the brains of women
with pre-eclampsia can undergo structural and functional changes as a
result of pre-eclampsia with the suggestion that this may predispose to
developing neurological deWcits later in life (for a comprehensive re-
view see (Ijomone et al., 2018). However, aside from the maternal neu-
rological changes, there is increasing interest in the long-term changes
in brains of exposed oZspring. In rodent models, we have recently
shown that a mild prenatal hypoxia-ischemia insult which mirrors a spe-
ciWc aspect of the pre-eclamptic pathology just prior to delivery, did
not affect brain or birth weight, but led to social behavioural deWcits
in exposed oZspring at postnatal day 30 (Driscoll et al., 2018). The oZ-
spring also had elevations in circulating adrenocorticotropic hormone
and corticosterone indicating an exaggerated stress response, coupled
with elevations in IL-6 and IL-1 but not TNF- mRNA and protein in
the brain and blood samples (Driscoll et al., 2018), which have been
shown in a recent systematic review and meta-analysis to be elevated
in ASD (Masi et al., 2015). These cytokines may also contribute to the
evolution behavioural abnormalities in the post-natal period given that
postnatal administration of IL-1Ra protected against prenatal-LPS-in-
duced changes in brain development and associated functional deWcits
(Girard et al., 2012). These data suggest there may be long-term changes
in the brains of pre-eclampsia exposed oZspring, and characterising
these changes has been the focus of recent investigations in human pop-
ulations.
A recent imaging study has examined regional brain volumes and
cerebral vasculature of children aged 7 to 10 years after exposure to
pre-eclampsia (Ratsep et al., 2016). Specifically children that had been
exposed to pre-eclampsia (mean age = 9.79 ± 0.89 years; n = 10; 5
male, 5 female) were matched based on age and sex to those born from
an uncomplicated pregnancy (mean age = 9.66 ± 1.07 years; n = 10;
5 male, 5 female). This cohort then underwent magnetic resonance
(MR) imaging to identify any brain structural and vascular anatomic
differences. While there were no significant differences in total in-
tracranial brain volume between the control group and children from
mothers exposed to pre-eclampsia, the pre-eclampsia group had sig-
nificant larger regional brain volumes in Wve of twenty-one regions
analysed that included the cerebellum, temporal lobe, left amygdala,
right amygdala and the brainstem (Ratsep et al., 2016). It is important
to note however that there were no significant differences in gestational
age (controls = 39.47 ± 1.38 weeks vs. pre-eclampsia = 37.16 ± 3.34
weeks), there was a significant difference in birth weight (con-
trols = 3.42 ± 0.36 kg vs. pre-eclampsia = 2.67 ± 0.79 kg) in this study
which may have confounded these results (Ratsep et al., 2016).
Interestingly, however, these alterations in regional brain volumes
have also been reported in children with ASD (Ha et al., 2015; Lainhart,
2015). In particular, the increases in amygdala volume has been re-
ported in a number of studies (Nordahl et al., 2012). In addition, a re-
cent follow up study in this same cohort as Ratsep et al, employed dif-
fusion tensor MR imaging (DTI) to examine myelination patterns and
white matter connectivity and six brain regions of interest were iden-
tiWed for analysis by tractography (middle occipital gyrus, caudate nu-
cleus and precuneus, cerebellum, superior longitudinal fasciculus, and
cingulate gyrus) (Figueiro-Filho et al., 2017). They reported increased
tract volumes in a number of these brain regions including the supe-
rior longitudinal fasciculus, which is strongly related to language and
communication pathways (Kamali et al., 2014). Interestingly, while the
molecular mechanisms that underlying these neuroanatomical changes
are unknown, a recent study have shown that exposure of fetal cortical
neurons to serum of women with established pre-eclampsia lead to in-
creases in axonal growth and branching (Curran et al., 2018). This sug-
gests that pre-eclampsia exposure may alter neurodevelopmental trajec-
tories, but to our knowledge this causative basis of altered brain vol-
umes in oZspring exposed to pre-eclampsia are currently unknown and
in addition these studies require conWrmation in larger patient cohorts.
6. How might maternal in/ammation in pre-eclampsia alter
neurodevelopmental outcome?
Given the epidemiological evidence for an association between
pre-eclampsia and neurodevelopmental outcome, then a key question is
what are the mechanisms that mediate this association? Given that ma-
ternal inXammation is a core feature of the maternal pathophysiology of
pre-eclampsia (Lau et al., 2013) and systematic evidence has reported
maternal inXammation as a risk factor for ASD (Jiang et al., 2016), it
is possible that pre-eclampsia-induced maternal inXammation is a deter-
minant of fetal neurodevelopmental outcome.
Arguably IL-6 is one of the best characterised mediator of the im-
pacts of maternal inXammation on fetal neurodevelopmental outcome.
Animal models of maternal inXammation have shown that maternal
administration of the viral mimetic, poly(I:C), lead to elevations in
maternal and fetal IL-6 levels, and alter neurobehavioural outcomes
in the oZspring (Meyer et al., 2006). Blocking IL-6 sig
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nalling through maternal co-administration of anti-IL-6 antibodies with
poly(I:C), prevented the poly(I:C)-induced social deWcits and transcrip-
tional changes in the brains of exposed oZspring (Smith et al., 2007).
Interestingly there is also increased IL-6 expression and signalling in
the placenta in the poly(I:C) model suggesting that conditions that in-
crease maternal-placental IL-6 signalling may lead to detrimental effects
in the fetal brain (Hsiao and Patterson, 2011). This has recently been
addressed in an elegant study by (Wu et al., 2017) who addressed the
role of maternal IL-6. The authors crossed il-6⁠+/+ males with il-6⁠ / fe-
males (resulting in a pregnant dam who cannot mount an IL-6 response),
and in parallel crossed il-6⁠ / males with il-6⁠+/+ females (resulting in
a pregnant dam who can mount an IL-6 response). Poly(I:C) adminis-
tration to these pregnant dams led to increases in fetal brain IL-6 lev-
els only in oZspring from il-6⁠+/+ females (Wu et al., 2017). Moreover,
conditional deletion of the IL-6 receptor in the placental trophoblast
prevented the maternal poly(I:C)-induced fetal brain inXammatory re-
sponse, neuroanatomical changes and anti-social and repetitive/anxi-
ety-like behaviour in exposed oZspring (Wu et al., 2017).
While the majority of these studies have been carried out in ro-
dent models, a recent study in humans reported the association be-
tween maternal IL-6 in pregnancy and the structural connectivity of
frontolimbic circuitry, which is critical for socioemotional and cognitive
development, in thirty infants (Rasmussen et al., 2018). Specifically,
diffusion tensor imaging revealed that maternal IL-6 levels averaged
across pregnancy were inversely associated with fractional anisotropy
(a measure of brain connectivity) and oZspring cognition at 12 months
of age (Rasmussen et al., 2018). Other studies have also show that
third trimester maternal IL-6 levels, are associated with neonatal func-
tional connectivity and with both fetal heart rate variability and tod-
dler cognitive development (Spann et al., 2018). This is in agreement
with the report that higher average maternal IL-6 was prospectively
associated with larger right amygdala volume and selected stronger
bilateral amygdala connectivity (Graham et al., 2018). Interestingly,
larger newborn right amygdala volume and stronger left amygdala
connectivity mediated the association between higher maternal inter-
leukin-6 concentrations and lower impulse control at 24 months of
age (Graham et al., 2018). Moreover, mothers of children with ASD
with intellectual disability had significantly elevated mid-gestational
levels IL-6 (Jones et al., 2016). However while these correlations do
not prove causation, recent work has shown that maternal depressive
symptoms are associated with higher maternal inXammation, includ-
ing IL-6, which mediates the effect on maternal report of infant nega-
tive affect (Gustafsson et al., 2018). This study provides proof-of-princi-
ple that pre-eclampsia-induced elevations in maternal IL-6 may act as a
mediator of the pre-eclampsia-ASD association. Collectively these data
support the premise that fetal exposure to pre-eclampsia-induced alter-
ations in maternal IL-6 and maternal-placental IL-6 signaling may in-
crease the risk of adverse neurodevelopmental outcomes, and perhaps
even increase the risk of neurodevelopmental disorders in genetically
predisposed oZspring.
7. Conclusions and future perspectives
Future epidemiological research examining the association between
pre-eclampsia and ASD in particular and neurodevelopmental disor-
ders in general, should address the limitations and gaps in the cur-
rent literature we have recently discussed (Maher et al., 2018). In par-
ticular, large population-based cohort studies with valid methods to
identify women with HDP and children with ASD are needed. It is
important that such studies be able to adjust for key potential con-
founders such as maternal and paternal age, maternal body mass in-
dex, socio-economic status factors, behavioural factors, family his
tory of mental disorders, ethnic origin and maternal morbidity such as
diabetes. In addition, such studies should attempt to assess whether ob-
served associations between HDP and ASD is HDP type speciWc, whether
the association is speciWc to ASD, or ASD and other neurodevelopmen-
tal and psychiatric disorders. Whether other pregnancy complications
and early life events have effect modiWcation or mediation role in the
HDP-ASD association is worth investigating as such analyses may im-
prove our understanding of the association and the potential mecha-
nisms. Moreover an important gap in the literature is the potential im-
pact of antihypertensive medications on any observed association. In
other words, is the observed association between pre-eclampsia and
ASD related to the HDP or pharmacological treatments used during
pregnancy? This is an important question for future research.
In future work it will also be important to examine neuroanatomi-
cal and neurobehavioural outcomes across the life span using multiple
pre-clinical models of pre-eclampsia, and in clinical cohorts. While the
longitudinal nature of these studies are challenging in humans, imag-
ing and developmental assessments of adequately powered cohorts of
oZspring exposed to pre-eclampsia and appropriate matched controls
will be important given recent studies showing changes in the brains of
pre-eclampsia-exposed oZspring (Figueiro-Filho et al., 2017; Ratsep et
al., 2016). Combining this with animal modelling will allow the role of
maternal inXammation and in particular IL-6 as mediator of the associ-
ation to be determined, using elegant approaches reported by Wu et al
(Wu et al., 2017). It will also be important to not limit studies of po-
tential mediators to IL-6 and explore a range of other potential inXam-
matory mediators including but not limited to TNF- and IL-17 (Choi et
al., 2016; Jones et al., 2016). Moreover, given a recent study showing
that most significant genetic variants associated with schizophrenia con-
verge on a developmental trajectory sensitive to events that affect the
placental response to in utero stressors, including pre-eclampsia (Ursini
et al., 2018), understanding the placental response in pre-eclampsia and
how this may predict or be associated with neurodevelopmental out-
comes in pre-eclampsia-exposed oZspring (O KeeZe and Kenny, 2014),
will be important questions for future research.
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